Ana Paula Tagliari1,2, Enrico Ferrari1,3, Philipp K Haager1,4, Martin Oliver Schmiady1, Luca Vicentini1, Mara Gavazzoni1, Marco Gennari1,5, Lucas Jörg1,4, Ahmed Aziz Khattab6,7, Stefan Blöchlinger8, Francesco Maisano1, Maurizio Taramasso1. 1. Cardiac Surgery Department, University Hospital of Zurich, University of Zurich, 8091 Zurich, Switzerland. 2. Postgraduate Program in Health Sciences: Cardiology and Cardiovascular Sciences-Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035003, Brazil. 3. Cardiac Surgery Department, Cardiocentro Ticino, 6900 Lugano, Switzerland. 4. Cardiology Department, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland. 5. Cardiac Surgery Department, IRCCS Centro Cardiologico Monzino, 20138 Milan, Italy. 6. Cardiology Department, University Hospital of Zurich, University of Zurich, 8091 Zurich, Switzerland. 7. Cardiology Department, Cardiance Clinic, 8808 Pfäffikon, Switzerland. 8. Cardiology Department, Kantonsspital Winterthur KSW, 8400 Winterthur, Switzerland.
Abstract
BACKGROUND: Cerebral embolic protection devices (CEPDs) have emerged as a mechanical barrier to prevent debris from reaching the cerebral vasculature, potentially reducing stroke incidence. Bovine aortic arch (BAA) is the most common arch variant and represents challenge anatomy for CEPD insertion during transcatheter aortic valve replacement (TAVR). METHODS: Cohort study reporting the SentinelTM Cerebral Protection System insertion's feasibility and safety in 165 adult patients submitted to a transfemoral TAVR procedure from April 2019 to April 2020. Patients were divided into 2 groups: (1) BAA; (2) non-BAA. RESULTS: Median age, EuroScore II, and STS score were 79 years (74-84), 2.9% (1.7-6.2), and 2.2% (1.6-3.2), respectively. BAA was present in 12% of cases. Successful two-filter insertion was 86.6% (89% non-BAA vs. 65% BAA; p = 0.002), and debris was captured in 95% (94% non-BAA vs. 95% BAA; p = 0.594). No procedural or vascular complications associated with Sentinel insertion and no intraprocedural strokes were reported. There were two postprocedural non-disabling strokes, both in non-BAA. CONCLUSION: This study demonstrated Sentinel insertion feasibility and safety in BAA. No procedural and access complications related to Sentinel deployment were reported. Being aware of the bovine arch prevalence and having the techniques to navigate through it allows operators to successfully use CEPDs in this anatomy.
BACKGROUND:Cerebral embolic protection devices (CEPDs) have emerged as a mechanical barrier to prevent debris from reaching the cerebral vasculature, potentially reducing stroke incidence. Bovine aortic arch (BAA) is the most common arch variant and represents challenge anatomy for CEPD insertion during transcatheter aortic valve replacement (TAVR). METHODS: Cohort study reporting the SentinelTM Cerebral Protection System insertion's feasibility and safety in 165 adult patients submitted to a transfemoral TAVR procedure from April 2019 to April 2020. Patients were divided into 2 groups: (1) BAA; (2) non-BAA. RESULTS: Median age, EuroScore II, and STS score were 79 years (74-84), 2.9% (1.7-6.2), and 2.2% (1.6-3.2), respectively. BAA was present in 12% of cases. Successful two-filter insertion was 86.6% (89% non-BAA vs. 65% BAA; p = 0.002), and debris was captured in 95% (94% non-BAA vs. 95% BAA; p = 0.594). No procedural or vascular complications associated with Sentinel insertion and no intraprocedural strokes were reported. There were two postprocedural non-disabling strokes, both in non-BAA. CONCLUSION: This study demonstrated Sentinel insertion feasibility and safety in BAA. No procedural and access complications related to Sentinel deployment were reported. Being aware of the bovine arch prevalence and having the techniques to navigate through it allows operators to successfully use CEPDs in this anatomy.
Authors: Aditya Muralidharan; Karthy Thiagarajan; Raymond Van Ham; Thomas G Gleason; Suresh Mulukutla; John T Schindler; Vinodh Jeevanantham; Parthasarathy D Thirumala Journal: Am J Cardiol Date: 2016-07-18 Impact factor: 2.778
Authors: Rutger-Jan Nuis; Nicolas M Van Mieghem; Carl J Schultz; Adriaan Moelker; Robert M van der Boon; Robert Jan van Geuns; Aad van der Lugt; Patrick W Serruys; Josep Rodés-Cabau; Ron T van Domburg; Peter J Koudstaal; Peter P de Jaegere Journal: Am J Cardiol Date: 2012-03-15 Impact factor: 2.778
Authors: Nicolas M Van Mieghem; Nahid El Faquir; Zouhair Rahhab; Ramón Rodríguez-Olivares; Jeroen Wilschut; Mohamed Ouhlous; Tjebbe W Galema; Marcel L Geleijnse; Arie-Pieter Kappetein; Marguerite E I Schipper; Peter P de Jaegere Journal: JACC Cardiovasc Interv Date: 2015-04-27 Impact factor: 11.195
Authors: Samir Kapadia; Shikhar Agarwal; D Craig Miller; John G Webb; Michael Mack; Stephen Ellis; Howard C Herrmann; Augusto D Pichard; E Murat Tuzcu; Lars G Svensson; Craig R Smith; Jeevanantham Rajeswaran; John Ehrlinger; Susheel Kodali; Raj Makkar; Vinod H Thourani; Eugene H Blackstone; Martin B Leon Journal: Circ Cardiovasc Interv Date: 2016-09 Impact factor: 6.546
Authors: Arie Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: Eur J Cardiothorac Surg Date: 2012-10-01 Impact factor: 4.191